BioWa licenses Potelligent technology to Novartis

The license provides Novartis with access to BioWa’s Potelligent technology platform to research, develop, manufacture, and commercialize antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibodies for an undisclosed number of targets.

In return, BioWa will receive license fees, development milestone payments and royalties on products developed by Novartis.

Masamichi Koike, president and CEO of BioWa, said: “We believe that this agreement significantly helps us to maximize the value of Potelligent technology and to fulfill our mission to bring the benefit of the technology to patients in need as quickly as possible.”